Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enhanced Omicron Variant Neutralization by a Human Antibody Tailored to Wild-Type and Delta-Variant SARS-CoV-2 RBDs.

Molecular pharmaceutics - 2 Sept 2024

Lee Jisun, Kim Bomi, Woo Hye-Min, Kim Jun-Won, Jung Inji, Park Seong-Wook, Kim Yong-Sung, Na Jung-Hyun, Jung Sang Taek

Abstract excerpt

Given the previous SARS-CoV-2 pandemic and the inherent unpredictability of viral antigenic drift and shift, preemptive development of diverse neutralizing antibodies targeting a broad spectrum of epitopes is essential to ensure immediate therapeutic and prophylactic interventions during emerging outbreaks. In this study, we present a monoclonal antibody engineered for cross-reactivity to both wild-type and Delta...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing
Share to Antibodies, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross Reactions

Share to Epitopes

Share to Neutralization Tests

Share to Protein Domains

Share to SARS-CoV-2

Share to Spike Glycoprotein, Coronavirus

Source

Identifiers

PMID: 39058261
DOI: 10.1021/acs.molpharmaceut.4c00297

Genes

ACE2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enhanced Omicron Variant Neutralization by a Human Antibody Tailored to Wild-Type and Delta-Variant SARS-CoV-2 RBDs.PMID 39058261Read ↗

Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH DomainsSemantic proximity Read ↗

A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation.Semantic proximity Read ↗

Somatic evolution of a cross-reactive germline antibody that expands its breadth to neutralize new SARS-CoV-2 variantsSemantic proximity Read ↗

Structural basis of Omicron neutralization by affinity-matured public antibodiesSemantic proximity Read ↗

Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variantsSemantic proximity Read ↗

Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariantsSemantic proximity Read ↗

Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variantsSemantic proximity Read ↗

Potent neutralization by a receptor binding domain monoclonal antibody with broad specificity for SARS-CoV-2 JN.1 and other variantsSemantic proximity Read ↗

Optimizing a Human Monoclonal Antibody for Better Neutralization of SARS-CoV-2Semantic proximity Read ↗

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variantsSemantic proximity Read ↗

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodiesSemantic proximity Read ↗

One Thousand SARS-CoV-2 Antibody Structures Reveal Convergent Binding and Near-Universal Immune EscapeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.